{
    "clinical_study": {
        "@rank": "83967", 
        "arm_group": [
            {
                "arm_group_label": "Mycophenolate sodium", 
                "arm_group_type": "Active Comparator", 
                "description": "Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium, and late introduction of tacrolimus"
            }, 
            {
                "arm_group_label": "Everolimus", 
                "arm_group_type": "Experimental", 
                "description": "Induction therapy with Thymoglobulin, prednisone, everolimus, and late introduction of tacrolimus."
            }
        ], 
        "brief_summary": {
            "textblock": "The disparity between supply and demand for organs has stimulated the development of\n      strategies to increase the availability of kidney grafts. Such strategy involves the use of\n      kidneys with expanded donor criteria (EDC). This is a study initiated by the investigator,\n      open, prospective, randomized, single center designed to compare the safety and efficacy of\n      two immunosuppressive regimens based on thymoglobulin, tacrolimus and everolimus versus\n      thymoglobulin, tacrolimus and mycophenolate sodium in renal transplant recipients with donor\n      criteria expanded."
        }, 
        "brief_title": "Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Kidney Transplantation", 
            "Cytomegalovirus"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults (> 18 years) candidates to renal transplant with expanded criteria deceased\n             donors;\n\n          -  Low risk of acute rejection, defined as first kidney transplant recipients and Panel\n             Reactive Antibody (PRA) <50%.\n\n          -  Signature of the informed consent form (ICF)\n\n        Exclusion Criteria:\n\n          -  Patients receiving immunosuppressive therapy before transplantation;\n\n          -  Patients who have received an investigational drug within last 30 days;\n\n          -  Patients with a known contraindication to the administration of an anti-thymocyte\n             globulin;\n\n          -  Patients with a positive test for human immunodeficiency virus (HIV);\n\n          -  Patients who had cancer (except non-melanoma skin cancer) within last two years;\n\n          -  Pregnant women, breastfeeding women, and women of childbearing potential unwilling to\n             use condoms or oral contraceptives will be excluded;\n\n          -  Patients with any Panel Reactive Antibody (PRA) equal to or higher than 50%, class I\n             or class II, will also be excluded;\n\n          -  Patients with positive test for parasites (protozoa and helminths)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895049", 
            "org_study_id": "CRAD001ABR32T"
        }, 
        "intervention": [
            {
                "arm_group_label": "Everolimus", 
                "intervention_name": "Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Mycophenolate sodium", 
                "intervention_name": "Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Immunosuppressive Agents", 
                "Mycophenolate mofetil", 
                "Everolimus", 
                "Sirolimus", 
                "Tacrolimus", 
                "Mycophenolic Acid", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Tacrolimus", 
            "Everolimus", 
            "Cytomegalovirus", 
            "Thymoglobulin", 
            "Deceased donors", 
            "Expanded criteria"
        ], 
        "lastchanged_date": "July 4, 2013", 
        "location": {
            "contact": {
                "email": "claudiafelipe@medfarm.com.br", 
                "last_name": "Claudia R Felipe, PhD", 
                "phone": "55 11 5087-8113"
            }, 
            "contact_backup": {
                "email": "nagilla.oliveira@medfarm.com.br", 
                "last_name": "Nagilla I Oliveira, Master", 
                "phone": "55-11-5087-8113"
            }, 
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "zip": "04038-002"
                }, 
                "name": "Hospital do Rim e Hipertensao"
            }, 
            "investigator": {
                "last_name": "Helio Tedesco, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "heliotedesco@hrim.com.br", 
            "last_name": "Helio Tedesco, PhD", 
            "phone": "55-11-5087-8113"
        }, 
        "overall_contact_backup": {
            "email": "claudiafelipe@medfarm.com.br", 
            "last_name": "Claudia R Felipe, PhD", 
            "phone": "55-11-5087-8113"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil:ANVISA"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of CMV disease or infection during the first year of transplantation.", 
            "measure": "Incidence of CMV disease", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895049"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital do Rim e Hipertens\u00e3o", 
            "investigator_full_name": "Helio Tedesco Silva Junior", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "To compare the two immunosuppressive regimens for the incidence of treatment failure defined as the composite endpoint of BPAR (biopsy-proven acute rejection), graft loss, death and loss to follow-up.", 
            "measure": "incidence of treatment failure", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Hospital do Rim e Hipertens\u00e3o", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Novartis", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Sanofi", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Helio Tedesco Silva Junior", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}